HOME > BUSINESS
BUSINESS
- Asahi Kasei Sues Endo over Xiaflex Supply Halt
October 2, 2019
- Axcelead Gets Its Hands on PassPort’s Transdermal Drug Delivery Technology
October 2, 2019
- Taisho Grabs Japan Rights to Moberg’s Topical Onychomycosis Drug
October 2, 2019
- Nippon Zoki to Develop Its 1st Biologic by Licensing Bone Forming Promoting Drug from South Korean Biotech
October 2, 2019
- Eisai, US Merck Present Final PII Results for Lenvima/Keytruda Combo for Endometrial Cancer
October 2, 2019
- Tsuyoshi Mitsuhashi Appointed as New President of Konica Minolta Precision Medicine
October 2, 2019
- Opdivo Significantly Extends OS against Chemo in Esophageal Cancer
October 2, 2019
- Takara Bio Drops Oncolytic Virus Filing for Melanoma in Japan
October 1, 2019
- ADC-Keytruda Combo Shows ORR of 71% in 1st Line Bladder Cancer: Astellas/Seattle Genetics
October 1, 2019
- Avanir’s AVP-786 Misses Goals in PIII for Moderate-to-Severe Agitation in AD Patients
October 1, 2019
- Eisai, Nichi-Iko Team Up for Generic Business in China
October 1, 2019
- AZ to Focus on Asthma-COPD Overlap in Marketing Triple-Combo Therapy Breztri, Will Help GPs Make Diagnosis
September 30, 2019
- GSK Recalls Zantac as Preventive Measure for NDMA Carcinogenic Risk
September 30, 2019
- Nippon Shinyaku Submits Sakigake DMD Drug Viltolarsen in Japan, Could Be Approved by March
September 27, 2019
- Meiji Seika’s Korean JV Passes GMP Inspection by PMDA, Preparing for Contract Production of Nesp Biosimilar
September 27, 2019
- Otsuka Files for Abilify Once-Monthly Injection for Bipolar Disorder in Japan
September 27, 2019
- Takeda’s Sakigake-Designated Narcolepsy Drug Prolongs Sleep Latency in PI
September 27, 2019
- Entyvio Shows Superiority to Humira in Clinical Remission in Comparison Study: Takeda
September 27, 2019
- Amid Slow Uptake, Sysmex Pitching Its Genomic Profiling via Close Communications with Hospitals, Govt: Exec
September 27, 2019
- Takeda’s TAK-620 Shows Antiviral Activities for CMV Infection in PII
September 26, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
